Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma

Shibata,Yoshihiro; Baba,Eishi; Ariyama,Hiroshi; Arita,Shuji; Isobe,Taichi; Kusaba,Hitoshi; Mitsugi,Kenji; Nakano,Shuji; Akashi,Koichi

doi:10.3892/ol_00000074

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma

Authors:
- Yoshihiro Shibata
- Eishi Baba
- Hiroshi Ariyama
- Shuji Arita
- Taichi Isobe
- Hitoshi Kusaba
- Kenji Mitsugi
- Shuji Nakano
- Koichi Akashi
View Affiliations

Affiliations: First Department of Internal Medicine and Department of Biosystemic Science of Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Published online on: May 1, 2010 https://doi.org/10.3892/ol_00000074
Pages: 423-426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic small intestinal adenocarcinoma (SIA) is rare among digestive tract malignancies, and a standard therapy has yet to be established. The present study described a patient who was treated with irinotecan-based chemotherapy. A 67-year-old woman with a long history of anemia was diagnosed as having SIA using small bowel endoscopy. Tumor invasion of the mesentery and multiple metastases to the lungs and peritoneal lymph nodes were detected. Nine courses of chemotherapy, each consisting of bolus infusion of 5-fluorouracil at 500 mg/m2, plus infusion of irinotecan at 100 mg/m2 with l-leucovorin at 20 mg/m2 on days 1, 8 and 15, were administered at 4-weekly intervals postoperatively. After two courses, the metastatic nodules in the lungs showed a decrease in number and size, and this response continued for over 6 months. Adverse events were manageable during this period. The patient succumbed to the disease 12 months after the initial diagnosis. The present results therefore suggest that irinotecan-based chemotherapy is a potential treatment for metastatic SIA.

View Figures

View References

1	Sager GF: Primary malignant tumors of the small intestine. A twenty-two year experience with thirty patients. Am J Surg. 135:601–603. 1978.PubMed/NCBI
2	Ciccarelli O, Welch JP and Kent GG: Primary malignant tumors of the small bowel. The Hartford Hospital experience, 1969–1983. Am J Surg. 153:350–354. 1987.PubMed/NCBI
3	Jemal A, Murray T, Ward E, et al: Cancer statistics. CA Cancer J Clin. 55:2592005.
4	Kusumoto H, Takahashi I, Yoshida M, et al: Primary malignant tumors of the small intestine: analysis of 40 Japanese patients. J Surg Oncol. 50:139–143. 1992. View Article : Google Scholar : PubMed/NCBI
5	Dabaja BS, Suki D, Pro B, Bonnen M and Ajani J: Adenocarcinoma of the small bowel: presentation, prognostic factors and outcome of 217 patients. Cancer. 101:518–526. 2004. View Article : Google Scholar : PubMed/NCBI
6	Polyzos A, Kouraklis G, Giannopoulos A, Bramis J, Delladetsima JK and Sfikakis PP: Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother. 15:503–506. 2003.PubMed/NCBI
7	Jigyasu D, Bedikian AY and Stroehlein JR: Chemotherapy for primary adenocarcinoma of the small bowel. Cancer. 53:23–25. 1984. View Article : Google Scholar : PubMed/NCBI
8	Onodera H, Nishitai R, Shimizu K, Maetani S and Imamura M: Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case. Surg Today. 27:60–63. 1997. View Article : Google Scholar : PubMed/NCBI
9	Lioe TF and Biggart JD: Primary adenocarcinoma of the jejunum and ileum: clinicopathological review of 25 cases. J Clin Pathol. 43:533–536. 1990. View Article : Google Scholar : PubMed/NCBI
10	Talamonti MS, Goetz LH, Rao S and Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg. 137:564–571. 2002. View Article : Google Scholar : PubMed/NCBI
11	Overman MJ, Kopetz S, Wen S, et al: Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 113:2038–2045. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fishman PN, Pond GR, Moore MJ, et al: Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol. 29:225–231. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gibson MK, Holcroft CA, Kvols LK and Haller D: Phase II study of 5-fluorouracil, doxorubicin and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 10:132–137. 2005. View Article : Google Scholar : PubMed/NCBI
14	Overman MJ, Varadhachary GR, Kopetz S, et al: Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 27:2598–2603. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ono M, Shirao K, Takashima A, et al: Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer. 11:251–255. 2008.PubMed/NCBI
16	Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK and Miller LL: Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist. 6:81–91. 2001. View Article : Google Scholar : PubMed/NCBI
17	Fujishima H, Kikuchi I, Miyanaga O, Ueda A, Baba E, Mitsugi K, Harada M and Nakano S: Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer. Int J Clin Oncol. 9:92–97. 2004. View Article : Google Scholar : PubMed/NCBI
18	Fujishima H, Makiyama A, Miyanaga O, Ueda A, Esaki T, Mitsugi K, Baba E, Kusaba H, Harada M and Nakano S: A multicenter phaseIIstudy of irinotecan (CPT-11) and bolus 5-fluorouracil (5FU)/l-leucovorin(l-LV) in patients with metastatic colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 23(16): Part I of II. 37422005.
19	Di Marco L, Berghenti M and Felloni M: Primary adenocarcinoma of the second portion of duodenum. Ann Ital Chir. 74:573–577. 2003.PubMed/NCBI
20	Zhou Z, Wan D and Shi M: Diagnosis and treatment of primary malignant tumors of the small bowel. Zhonghua Zhong Liu Za Zhi. 19:297–299. 1997.PubMed/NCBI
21	Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30. 2004. View Article : Google Scholar
22	Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI